Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
251.48
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
December 31, 2021
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...
Via
Benzinga
51 Biggest Movers From Yesterday
December 28, 2021
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 27, 2021
Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 47.87% to $8.02 during Monday's regular session. The current volume of 63.6 million shares is 153229.83%...
Via
Benzinga
34 Stocks Moving In Monday's Mid-Day Session
December 27, 2021
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares jumped 69.6% to $9.19 after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY...
Via
Benzinga
BridgeBio Pharma Stock Crashes As Pfizer-Rivaling Heart Drug Flops
December 27, 2021
Patients who received the drug didn't improve in the six-minute walking test.
Via
Investor's Business Daily
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol
December 23, 2021
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is...
Via
Benzinga
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
December 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...
Via
Benzinga
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
December 14, 2021
Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its ...
Via
Benzinga
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
November 22, 2021
RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) to Outperform from Sector Perform with a price target of $225, up from $144. While M...
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022
November 22, 2021
Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.
Via
Investor's Business Daily
Expert Ratings For Alnylam Pharmaceuticals
November 22, 2021
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 22, 2021
November 22, 2021
Upgrades According to Evercore ISI Group, the prior rating for Kimco Realty Corp (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Monday
November 22, 2021
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...
Via
Benzinga
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Dicerna Stock Rockets On Novo Nordisk's $3.3 Billion Takeover Plan
November 18, 2021
Novo Nordisk is buying an RNA interference company.
Via
Investor's Business Daily
Where Alnylam Pharmaceuticals Stands With Analysts
November 01, 2021
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ra...
Via
Benzinga
Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript
October 29, 2021
ALNY earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Alnylam Pharmaceuticals Stock Is Tanking This Week
October 29, 2021
The company missed analysts' Q3 revenue expectations and announced the departure of its CEO.
Via
The Motley Fool
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
66 Biggest Movers From Yesterday
October 29, 2021
Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug...
Via
Benzinga
Why Alnylam Pharmaceuticals Is Crashing Today
October 28, 2021
The company's earnings fell short of expectations and its CEO is leaving.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
October 28, 2021
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 21.62% to $2.25 during Thursday's regular session. Trading volume for Kiromic BioPharma's stock is...
Via
Benzinga
Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit
October 28, 2021
Alnylam fell on a disappointing quarter and plans for CEO John Maraganore to exit.
Via
Investor's Business Daily
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
3 Growth Stocks Near 52-Week Highs to Buy Anyway
October 14, 2021
These top performers have what it takes to keep providing outsized gains for patient investors.
Via
The Motley Fool
Where Alnylam Pharmaceuticals Stands With Analysts
October 12, 2021
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:
Via
Benzinga
10 Health Care Stocks With Unusual Options Alerts In Today's Session
October 08, 2021
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.